0000899243-20-008429.txt : 20200316 0000899243-20-008429.hdr.sgml : 20200316 20200316160222 ACCESSION NUMBER: 0000899243-20-008429 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200312 FILED AS OF DATE: 20200316 DATE AS OF CHANGE: 20200316 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Konidaris Tasos CENTRAL INDEX KEY: 0001320982 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38485 FILM NUMBER: 20717051 MAIL ADDRESS: STREET 1: 103 JFK PARKWAY CITY: SHORT HILLS STATE: NJ ZIP: 07078 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Amneal Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001723128 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 BUSINESS ADDRESS: BUSINESS PHONE: (908) 947-3120 MAIL ADDRESS: STREET 1: 400 CROSSING BOULEVARD STREET 2: 3RD FLOOR CITY: BRIDGEWATER STATE: NJ ZIP: 08807 FORMER COMPANY: FORMER CONFORMED NAME: Atlas Holdings, Inc. DATE OF NAME CHANGE: 20171117 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-03-12 0 0001723128 Amneal Pharmaceuticals, Inc. AMRX 0001320982 Konidaris Tasos C/O AMNEAL PHARMACEUTICALS, INC. 400 CROSSING BOULEVARD, 3RD FLOOR BRIDGEWATER NJ 08807 0 1 0 0 SVP and CFO Restricted Stock Units 2020-03-12 4 A 0 350877 0.00 A Class A Common Stock 350877 350877 D Performance-Based Restricted Stock Units 2020-03-12 4 A 0 701754 0.00 A Class A Common Stock 701754 701754 D Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. The restricted stock units vest in four equal annual installments beginning on March 12, 2021. Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Represents the maximum number of shares issuable under the performance-based restricted stock units. 25% of the performance-based restricted stock units are earned and eligible to vest upon the Issuer's Class A Common Stock achieving an average closing price per share of $8 or higher for 60 consecutive calendar days during the three-year performance period. An additional 12.5% of the performance-based restricted stock units are earned and eligible to vest upon the Issuer's Class A Common Stock achieving an average closing price per share of $10, $12, $14, $16, $18 and $20, respectively, for 60 consecutive calendar days during the three-year performance period. For average 60-day closing stock prices between $12 and $20 per share, the number of performance-based restricted stock units that become earned will be determined using straight line interpolation. Any earned performance-based restricted stock units vest in full on February 28, 2023, the last day of the performance period. /s/ Meredith Cook, Attorney-in-Fact 2020-03-16